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Imidazolium-labeled Glycosides as Probes to Harness 
Glycosyltransferase Activity in Human Breast Milk  
I. Sittela and M. C. Galan*a 
Imidazolium-labeled (ITag-) glycosides are used to harness the 
glycosyltransferase activity directly from human breast milk. The 
covalently attached ionic labels provide a bifunctional chemical handle 
that is used to monitor reaction progress by MS, as well as aid in 
product purification from complex mixtures. The technology is 
exemplified in the synthesis of biologically relevant oligosaccharide 
analogs, ITag-LacNAc, ITag-Lewisx and ITag-Lewisa, in a matter of days 
from human breast milk without having to isolate specific enzymes. 
The growing appreciation of oligosaccharides and 
glycoconjugates as key mediators in many important biological 
processes from cell signaling, embryogenesis, neural 
development to pathogen recognition, inflammation, innate 
immune responses and cancer, has lead to their use as probes 
for biological research and as key compounds for drug and 
vaccine development.1 Despite the many recent advances in the 
field, progress in this area is still impeded by a lack of general 
and efficient methods for the routine preparation of complex 
oligosaccharides. Traditional chemical approaches rely on 
lengthy and time consuming chemical steps to achieve good 
yields and stereocontrol.2 On the other hand, the use of 
carbohydrate processing enzymes such as glycosyltransferases, 
to construct oligosaccharides offers several advantages over 
chemical approaches, since these enzymes are able to form 
glycosidic bonds with exquisite regio- and stereocontrol by 
catalyzing the transfer of an activated sugar donor to growing 
oligosaccharide chains without the need for protecting 
groups.2d,3  However, access to these enzymes is limited as the 
proteins can be challenging to express, expensive to employ on 
scale and only a handful are currently commercially available.4  
 Human breast milk (HBM) is an extremely complex and 
highly variable biofluid comprised of carbohydrates, proteins, 
lipids and enzymes, which has evolved over millennia to nourish 
infants and protect them from disease, whilst their own 
immune system matures.5  HBM contains more than 200 
different unbound human milk oligosaccharides (HMOs),5b,6 
consisting of five monosaccharide building blocks: galactose 
(Gal), glucose (Glc), N-acetylglucosamine (GlcNAc), fucose (Fuc) 
and sialic acid (Neu5Ac). All HMOs carry lactose (Gal-1,4-Glc) 
at the reducing end, which can be elongated through a -1,3- or 
-1,6-linkage by two different disaccharides, either Gal-1,3-
GlcNAc (lacto-N-biose, type 1 chain) or Gal-1,4-GlcNAc (N-
acetyllactosamine (LacNAc, type 2 chain). Further chain 
elongation can take place by the incorporation of Fuc and 
Neu5Ac units.7 Our understanding of the biosynthesis of these 
oligosaccharides is limited, since most of the specific 
glycosyltransferases that are responsible for the formation of 
HMO structures with specific glycosidic linkages have not been 
identified.7b,8 In addition, HMO-specific glycosyltransferase 
expression levels are determined by the blood group, diet and 
environmental and genetic factors as well as lactational period 
of the donor.7a,9  
 Figure 1. General strategy to harness glycosyltransferase activity in human 
breast milk.  
 
 Ionic liquid-based labels have emerged as a new class of 
chemical labels that can be employed for the immobilization 
and mass spectrometry (MS) detection of reagents from 
complex reaction mixtures, due to their unique physical and 
chemical properties.10 Our group10c,11 and others12 have 
reported the synthesis of inexpensive and versatile 
imidazolium-based tags (ITags) and their application to 
chromatography-free chemical oligosaccharide synthesis. 
Furthermore, in our work, we demonstrated that the cationic 
labels are also compatible with enzymatic transformations and 
that ITag-glycoside substrates could be employed for the 
qualitative and quantitative reaction monitoring, using MS 
-1,4-galactosyltransferase (-1,4-
GalT)13, human -1,3-fucosyl-transferase (-1,3-FucT VI)14  and 
α-2,3-sialyltransferase (α-2,3-ST) from pasteurella multocida, as 
well as α-2,6-sialyl-transferase (α-2,6-ST)15 from 
photobacterium damsel. More recently, ITag-labeled 
mannosamine was also employed for the non-covalent 
labeling of live cells,16 demonstrating the versatility of the 
probes. 
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Scheme 1. One-pot in vitro chemo-enzymatic synthesis of ITagged human milk 
oligosaccharides 3, 4 and 9. See ESI Fig. S1 for traces. 
 
 Encouraged by the simplicity and practicality of the 
approach, we hypothesized that ITag-glycan probes would be 
ideally suited to harness the biosynthetic machinery (e.g. 
glycosyltransferases) present in HBM, and thus gain expedient 
access to biologically important oligosaccharides, without the 
need to isolate or express specific enzymes. 
 Initial experiments began by assessing our ability to monitor 
mixtures of ITag-glycoside products that had been generated in 
vitro in a multi-enzyme environment. To that end, 
methylimidazolium N-benzenesulfonyl-linked GlcNAc (GlcNAc-
ITag) 1, which was prepared in 4 steps and 59% overall yield 
from azidopropyl GlcNAc 615 (see ESI for details), was incubated 
in 3-morpholinopropane-1-sulfonic acid (MOPS) buffer (pH 7.8) 
at 37˚C with three different recombinant enzymes: -1,4-GalT, 
which catalyzes the transfer of galactose from uridine 5’-
diphosphogalactose (UDP-Gal) to C4 of GlcNAc to yield ITag-
LacNAc 3; -2,3-SialylT, which in the presence of cytidine 5’-
monophospho-N-acetylneuraminic acid (CMP-Neu5Ac) will add 
Neu5Ac at C3’ of the LacNAc disaccharide to yield 3’-Sialyl-
LacNAc-ITag 9 -1,3-FucT VI, which can fucosylate 3 at C3 
of the GlcNAc unit in the presence of guanosine 5’-diphospho-
-L-fucose (GDP-Fuc) to form the  
ITag-LewisX trisaccharide [Fuc-1,3-(Gal-1,4-)GlcNAc] 4 or 
generate Sialyl-LewisX 10 from 917 (Scheme 1). Incubations were 
carried out in the presence of an excess of an equimolar mixture 
of UDP-Gal, CMP-Neu5Ac and GDP-Fuc, which was added 
portion-wise over 3 days. LC-MS was used to analyze and 
monitor reaction progress. Four different ITagged species were 
identified in the mixture: starting material 1 ([M+] 513), LacNAc-
ITag 3 ([M+] 675) and trisaccharides 4 ([M+] 821) and 9 ([M+] 
966) in a ratio of 12:42:2:44 for 1:3:4:9 as determined by LC-MS. 
Comparison of retention times and MS data to that of isolated 
ITag-materials,13-15 confirmed the structure identity of the 
individual ITag-glycosides. 
   
 
Scheme 2. Incubation of GlcNAc-ITag 1 and LacNAc-ITag 3 with UDP-Gal and 
GDP-Fuc, respectively, in HBM and LC-MS traces of A) total ion count of HBM 
incubation of 1 without addition of UDP-Gal; B) extracted LC–MS trace for 1 (M+ 
513) before addition of UDP-Gal; C) extracted LC–MS trace for 3 (M+ 675) after 5 
days of incubation with 1 and UDP-Gal; D) extracted LC–MS trace for 4 (M+ 821) 
after 17 days of incubation with 3 and GDP-Fuc. 
 
 Having demonstrated that we are able to detect ITag-
glycosylation products from complex enzymatic mixtures, even 
at low concentrations (M), GlcNAc-ITag 1, which is a common 
motif in both type 1 and type 2 HMO chains,7a was used as a 
decoy to hijack glycosyltransferase activity in HBM. -linked 
GlcNAc units are further elongated in HMOs with a -1,3- or -
1,4-linked galactose unit. Thus 1 was incubated at 37˚C with 
unpasteurized HBM (1 mg/mL) in the presence of excess UDP- 
Gal (2.4 equiv.), which was added portion-wise over 5 days, in 
order to bias the production of galactosylated species (Scheme 
2). It is important to highlight that no reaction was observed 
without addition of the sugar nucleotide (Fig. S3 in ESI). To our 
delight, LC-MS analysis of the milk sample showed >86% 
conversion of 1 to a galactose-containing ITag-disaccharide (M+ 
675). Importantly, ITag-oligosaccharide products display 
significantly different retention times in reverse-phase HPLC 
from other components in HBM (including unlabeled HMOs) to 
allow their efficient isolation. NMR analysis of the purified ITag-
disaccharide confirmed the structure as -1,4-linked ITag-
LacNAc 3.18 No -1,3-linked galactose containing disaccharide 
was detected in the mixture, even though it is a common 
fragment found among HMOs.19 This could be attributed to a 
number of factors e.g. low concentrations of the specific 
enzyme in the milk sample, low activity of the enzyme towards 
our ITag-substrate or an increased hydrolase activity towards 
the -1,3-linked lacto-N-biose-ITag dimer.20  
 HMO fucosylation is a common modification, which is 
mostly dependent on the Lewis blood group of each individual 
donor. Milk donors can be divided into four different groups 
depending on their Lewis and secretor gene activity.21 The best 
known examples of fucosyltransferases found in HBM are -1,2-
fucosyltransferase (FUTII)22 and -1,3/4-fucosyltransferase 
(FUTIII),23 which are responsible for the formation of -1,2- and 
-1,3/4-linked fucosides, respectively, and Lewis gene-
independent α-1,3-fucosyltransferases.24 In order to target 
HBM fucosyltransferase activity, previously isolated ITag-
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LacNAc 3, which has been identified as a substrate for this class 
of enzymes, was incubated with excess GDP-Fuc in HBM as 
before (See ESI for full details). Excitingly, a new 
monofucosylated ITag-trisaccharide (M+ 821) structure was 
observed by LC-MS analysis, which, after 18 days of incubation 
and 18% conversion, was isolated. Following NMR 
characterization, this structure could be assigned to -1,3-
linked ITag-Lewisx derivative 4 (Scheme 2). No other fucosylated 
species were isolated, which is in agreement with the 
fucosylation pattern found in HBM for LacNAc dimers9b, 25 and 
the known specificity for HBM purified FUTIII.26 In addition to 
fucosyltransferase activity, α-fucosidase activity has also been 
identified in HBM27 and that might be accountable for the lower 
conversions observed. 
 
Scheme 3. Chemical synthesis of ITag-lacto-N-biose 2 
 
 Type 1, -1,3-linked disaccharide lacto-N-biose, is also found 
fucosylated in HBM.[28] Possible sites for fucosylation include 
the common -1,2-linkage to the terminal Gal residue of lacto-
N-biose, as well as at C4 to form an -1,4-linkage to the sub-
terminal GlcNAc unit; the latter is catalyzed by the same enzyme 
that transfers a fucose unit to C3 of LacNAc to form Lewisx.[22b] 
Since we did not observe any -1,3-linked disaccharides in our 
initial milk incubations with 1, we decided to synthetically 
prepare ITag-lacto-N-biose 2 (Scheme 3) and explore whether 
fucosyltransferases activity in the milk could be exploited in this 
instance. To that end, 4-(halomethyl)- benzenesulfonamide-
conjugate 8[14] was deacetylated using sodium methoxide in 
methanol. 4,6-O-benzylidene acetal protection, using 
benzaldehyde dimethylacetal and copper triflate as the 
catalyst,29 produced glycoside acceptor 11 in 77% yield over the 
two steps, with a 1:2 ratio of 11a:11b, ready to be glycosylated 
at C3. Chemical glycosylation of 11b with galactose trichloro-
acetimidate 12 afforded protected lacto-N-bioside 13 with 
complete -stereocontrol in a 54% yield. Disaccharide 13 was 
subsequently ITagged by SN2 halide displacement with 1-
methylimidazole to give 14 in 79% yield. Finally, global 
deprotection was carried out in two sequential steps: firstly 
acetal hydrolysis was performed with acetic acid/water, which 
was followed by acetate removal in the presence of sodium 
methoxide in methanol to reveal fully unprotected ITag-lacto-
N-biose 2 in 94% yield.  
 Milk incubation of 2 in the presence of an excess of GDP-Fuc 
(3 equiv.) in HBM was carried out as before and the reaction 
was monitored by LC-MS (Scheme 4). Delightfully, a new 
trisaccharide species was detected in the LC-MS trace, with a 
molecular weight consistent with a fucosylated lacto-N-biose 
moiety (M+ 821). A maximum conversion of 11% was observed 
after 16 days of incubation. After HPLC isolation and NMR 
structural characterization, we were able to assign the new 
trisaccharide to ITag-Lewisa 5 (Fuc-1,4-[Gal-1,3]-GlcNAc). It is 
likely that the enzyme responsible for fucosylation of both 
disaccharides 2 and 3 is -1,3/4-fucosyltransferase (FUTIII), 
which has been previously isolated from HBM.28,30  
 
 
Scheme 4. Incubation of ITagged 2 with GDP-Fuc in HBM to obtain ITag-Lewisa 
5 and LC-MS traces of: A) total ion count of HBM reaction mixture; B) extracted 
LC–MS trace for 2 and C) extracted LC–MS trace for 5. 
 
 In conclusion, although metabolic oligosaccharide pathways 
present a number of significant challenges, we have shown that 
imidazolium-labeled (ITag-) glycosides can be used to harness 
glycosyltransferase activity directly from human breast milk, 
without having to isolate the specific enzymes. We demonstrate 
that ITags covalently attached to glycoside substrates provide a 
bifunctional chemical handle that can be used to monitor 
reaction progress by MS, as well as aid in the purification of the 
products from complex mixtures. Using this technology, we 
were able to access a series of biologically important 
oligosaccharides, ITag-LacNAc, ITag-Lewisx and ITag-Lewisa, in a 
matter of days from a readily available source, human breast 
milk. We believe that these cationic probes offer a practical and 
novel technology to harness enzyme activity in complex 
biosynthetic pathways. We believe that the strategy showcased 
here will find applications in and beyond the field of 
carbohydrates.  
 Notes and references 
General procedure for HBM incubations: Acceptor (1, 2 or 3) 
and donor nucleotide (UDP-Gal or GDP-Fuc) were dissolved in 
HBM, which had been allowed to warm to 37 oC, and the mixture was 
incubated at 37 ˚C until no further conversion was observed. Donor 
nucleotide and fresh milk were added throughout the incubation 
period and in the case of fucosylated targets, the sample was freeze 
dried when no further conversion was observed and the reaction re-
started by addition of fresh milk and GDP-Fucose to the dried sample 
(see specific details in ESI). The reaction was then quenched by 
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cooling on ice and the mixture filtered with ISO-Disc Filters (N 4-2, 
Nylon 4 mm x 0.2 um) prior to analysis. 
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